Extended experience with a non‐cytotoxic DNMT1‐targeting regimen of decitabine to treat myeloid malignancies

The nucleoside analogue decitabine can deplete the epigenetic regulator DNA methyltransferase 1 (DNMT1), an effect that occurs, and is saturated at, low concentrations/doses. A reason to pursue this molecular‐targeted effect instead of the DNA damage/cytotoxicity produced with high concentrations/do...

Descripción completa

Detalles Bibliográficos
Autores principales: Awada, Hassan, Mahfouz, Reda Z., Kishtagari, Ashwin, Kuzmanovic, Teodora, Durrani, Jibran, Kerr, Cassandra M., Patel, Bhumika J., Visconte, Valeria, Radivoyevitch, Tomas, Lichtin, Alan, Carraway, Hetty E., Maciejewski, Jaroslaw P., Saunthararajah, Yogen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Haematological Malignancy – Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154732/
https://www.ncbi.nlm.nih.gov/pubmed/31736067
http://dx.doi.org/10.1111/bjh.16281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154732/
https://www.ncbi.nlm.nih.gov/pubmed/31736067
http://dx.doi.org/10.1111/bjh.16281

Ejemplares similares